University spin out company addresses new vaccines

August 8, 2017, University of Plymouth
Dr. Michael Jarvis, Chief Scientific Officer of The Vaccine Group. Credit: University of Plymouth

The University of Plymouth has launched a new spin out company which will address new vaccines for diseases which spread from animals to humans and for use in infection control.

Governments, pharmaceutical companies and supranational bodies are showing increasing concern about emerging infectious diseases. The Vaccine Group will exploit technology developed by Dr Michael Jarvis, Associate Professor in Virology and Immunology at the University of Plymouth, who specialises in the creative design of herpesvirus-based vaccines for the control of disease.

The Vaccine Group aims to commercialise new platforms for the development of vaccines for use in (such as bovine tuberculosis) and for a rapid response to pathogens which unpredictably cross the species barrier and pose a significant threat to . Target pathogens include avian influenza A, Ebola and Marburg viruses, MERS and SARS coronaviruses and Rift Valley fever virus.

Dr Jarvis' work has previously received funding from a number of sources, including UK Innovate, National Institutes of Health and the Medical Research Council. Initial work in The Vaccine Group will focus on herpesvirus-based platforms suitable for use in animals, to protect human health by targeting the animal species from which is transmitted to humans, for vaccination (termed zoonoses barrier vaccines). Future developments will include vaccines for use in humans.

Dr Michael Jarvis, Chief Scientific Officer of The Vaccine Group, said: "My laboratory has nearly 20 years' experience in the development of vaccines based on herpesvirus-based technology. Science is a collaborative endeavour, and The Vaccine Group provides a new vehicle by which we can interact with fellow scientists, industry and investors to prevent emergence of relevant to global human health and agriculture."

The Vaccine Group is supported by the University of Plymouth and the Frontier IP Group plc, which specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property.

Explore further: New study highlights effectiveness of a herpesvirus CMV-based vaccine against Ebola

Related Stories

New study highlights effectiveness of a herpesvirus CMV-based vaccine against Ebola

February 15, 2016
As the latest in a series of studies, researchers at Plymouth University, National Institutes of Health and University of California, Riverside, have shown the ability of a vaccine vector based on a common herpesvirus called ...

Could self-disseminating vaccines cut off emerging infectious diseases at source?

November 2, 2015
The 2014/2015 Ebola outbreak in West Africa shone the spotlight not only on the unpreparedness of local health services and science to deal with the pandemic, but also on the phenomenon of emerging infectious diseases (EIDs).

Researchers take an important step toward an HIV vaccine

May 17, 2017
Researchers from the University of Copenhagen have developed a strategy that can revolutionize vaccine design. The new strategy is used to develop vaccines that can prevent HIV infection and the development of AIDS.

New experimental vaccine produces immune response against MERS virus

April 30, 2014
The University of Maryland School of Medicine (UM SOM) and Novavax, Inc. today announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus ...

Recommended for you

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Discovery suggests new route to fight infection, disease

November 14, 2018
New research reveals how a single protein interferes with the immune system when exposed to the bacterium that causes Legionnaires' disease, findings that could have broad implications for development of medicines to fight ...

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.